Huang Huayue: the next biomedical center will be in Asia

[expert opinion of China Pharmaceutical network] as a regional economic expert, Huang Huayue has studied the biomedical industry for more than 20 years In his opinion, "the next biomedical center will be born in Asia." One reason why he is so confident in Asian countries is that Asian countries, including China, Japan and India, have positioned the biomedical industry as one of the key national development industries and given a lot of policy support (Huang Huayue: the next biomedical center will be in Asia) drive about 30 kilometers from Tianfu Square to the south, "Chengdu Tianfu international biological city" sign enters Huang Huayue's vision On October 26, as an important station of investigation in Chengdu, the director and general manager of Research Department of Milken Research Institute Asia Center walked into Tianfu international bio city under construction to have a glimpse of the development of Chengdu bio pharmaceutical industry Last week, Huang Huayue visited several industrial parks in Chengdu "What are the introduced teams", "how to distribute the income of intellectual property rights", "how to avoid being" borrowed "in policy design" In Tianfu international biological city, he has studied in the field of biomedicine for more than 20 years, almost instinctively focusing on the possible problems behind the industrial development In Huang's view, with the development of the industry, the next biomedical center may be born in Asia After learning about the development of Chengdu's biomedical industry, he said, "Chengdu is really blessed with the right time Basically everything you want to do can be realized." The open environment helps China compete for the global biomedical industry "After the information age, it will be the era of bioeconomy." With this prediction put forward by futurist Toffler becoming a consensus, as a global technology innovation is an active and far-reaching emerging industry, biomedical industry is being brought into a new round of development focus by various countries, from the European and American countries with solid foundation to the Asian countries with continuous innovation, all of which are competing vigorously As a regional economic expert, Huang Huayue has studied the biomedical industry for more than 20 years In his opinion, "the next biomedical center will be born in Asia." One reason why he is so confident in Asian countries is that Asian countries, including China, Japan and India, have positioned the biomedical industry as one of the key national development industries and given a lot of policy support For example, in China, many cities, including Beijing, Shanghai, Guangzhou, Chengdu and so on, have set up industrial parks in the name of "Medicine Valley" or "medicine base" At the same time, under the strong policy incentive, the burst of innovation vitality is an important reason for the rapid development of biomedical industry When communicating with the relevant principals of Chengdu Tianfu international biological city, Huang Huayue asked about the introduction of foreign experts In his view, in the biomedical industry with innovation as the core, through institutional and institutional reform, innovation and exploration of regulatory models in special fields and other ways, to create a relaxed and convenient research and development environment will help to enhance the attraction of international pharmaceutical talents "Stem cell research has a lot of restrictions in the United States and a lot of easing in China," he said Moreover, the pilot free trade zone being implemented in China has brought more benefits to pharmaceutical innovation Zhangjiang pharmaceutical Valley, located in Shanghai Free Trade Zone, explores the facilitation of import approval of biological reagents, reducing the original 20 days to 7 days "Free trade zone" has become the golden signboard for pharmaceutical enterprises and R & D institutions to enter For example, Chengdu area of Sichuan Free Trade Zone, which has been listed for more than half a year, has attracted world top 500 pharmaceutical enterprises, including MSD and Medtronic, to settle down and add codes Gathering resources, Chengdu is speeding up to build a hundred billion level biological industry cluster "Chengdu is really unique, and the time is right Basically everything you want to do can be realized." On October 26, after visiting Chengdu Tianfu international biological city, Huang Huayue said with emotion As one of the key development pillar industries in Chengdu, biomedical industry has developed rapidly in recent years In 2016, the city's biomedical manufacturing industry above Designated Size achieved sales revenue of 45 billion yuan As an important carrier of Chengdu's 100 billion level biological industry cluster, Tianfu international biological city is expected to be a great future According to the plan, Chengdu Tianfu international biological city will focus on biomedicine, biomedical engineering, biological services and intelligent health, strive to build a world-famous habitat for innovation and entrepreneurship talents in the biological industry, a capital of innovation and intelligent manufacturing in the biological industry, and an international life and health town According to the industrial plan, "strive to gather more than 200000 biological industry talents, more than 30000 enterprises and output value of more than 500 billion yuan by 2035." At present, after one and a half years of construction, the "bio-town" has gradually taken shape, gathering a lot of resources, including three Nobel Prize teams, two academician teams of the Chinese Academy of Sciences and the Chinese Academy of Sciences, 18 overseas high-level talent teams, more than 70 signed projects, and more than 90 billion investment attraction Just two weeks ago, Pfizer, an international pharmaceutical giant, announced to join hands with Chengdu pharmaceutical enterprises to invest in the construction of new drug R & D projects It is worth noting that this is Pfizer's attempt to develop new drugs through cooperation The head of Tianfu international bio city said that bio medicine is a highly knowledge, technology and talent intensive industry, especially the need to strengthen learning exchanges and strategic cooperation with global resources It is understood that another world top 500 pharmaceutical company has now decided to settle in Tianfu international biological city According to the plan, the first batch of buildings of Tianfu international biological city Incubation Park will be delivered in July next year As the time for enterprises to enter the site approaches, this industry and open cooperation highland will accelerate to rise in the south of Chengdu Original title: "the next biomedical center will be born in Asia"